Search Results



Your search for Ayalew Tefferi, MD matches 7 pages

Showing 1 - 7


ASH Honors J. Evan Sadler, MD, PhD, and Ayalew Tefferi, MD, With the 2016 Henry M. Stratton Medal

The American Society of Hematology (ASH) will recognize J. Evan Sadler, MD, PhD, of Washington University School of Medicine in St. Louis, and Ayalew Tefferi, MD, of Mayo Clinic College of Medicine, with the 2016 Henry M. Stratton Medal for their seminal contributions in the areas of basic and...

hematologic malignancies

Optimizing Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for myelofibrosis. The ASCO Post asked an expert in this field, Ayalew Tefferi, MD, how and when he uses stem cell transplant in myelofibrosis, which is a topic he outlined in greater detail in the...

hematologic malignancies

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 634, “Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study.”

hematologic malignancies

Ayalew Tefferi, MD, on New Models of Prognostication for Myelofibrosis

Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 403, “A Compendium of Cytogenetic Abnormalities in Myelofibrosis: Molecular and Phenotypic Correlates in 826 Patients;” abstract 406, “Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary...

hematologic malignancies

JAK2 and MPL Mutation Screening: What Are the Indications and How to Interpret the Results

The World Health Organization system organizes myeloid malignancies into five major categories, which are subsequently further subclassified using a combination of bone marrow morphology and cytogenetic/molecular information (Table 1).1 JAK2 and MPL mutations are not disease-specific and occur...

hematologic malignancies

How I Work up the Patient with Thrombocytosis

Thrombocytosis is defined as a platelet count greater than 400 × 109/L. In routine clinical practice, thrombocytosis is much more likely to be reactive (> 80% of cases) than primary. Reactive thrombocytosis is usually associated with infections, inflammation, trauma, hemolysis, metastatic...

hematologic malignancies

Telomerase Inhibitor Imetelstat Shows Activity in Myelofibrosis

In a pilot study reported in The New England Journal of Medicine, Tefferi et al found that imetelstat, which targets the RNA template of telomerase reverse transcriptase, produced responses in patients with myelofibrosis. Treatment was associated with myelosuppression in some patients. Current...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.